HK Stock Market Move | JD HEALTH (06618) up more than 6%, further upgrading cooperation with Jiangsu Yuyue Medical Equipment & Supply to further promote the integration of AI medical equipment into HomeCare service system.
JD Health (06618) rose by over 6%, as of the time of writing, it increased by 6.09%, closing at 36.26 Hong Kong dollars, with a trading volume of 441 million Hong Kong dollars.
As of the time of writing, JD HEALTH (06618) has risen by over 6%, with an increase of 6.09% to reach HK$36.26, with a trading volume of HK$4.41 billion.
On the news front, on July 2nd, according to JD HEALTH's official Weibo account, JD HEALTH and Jiangsu Yuyue Medical Equipment & Supply have further upgraded their cooperation in the "AI + medical equipment" field. Based on the rapid growth of core categories such as CGM and ECG monitors in the first half of this year, as well as the collaboration results in exclusive sales, new product launches, and co-creation of smart devices with JD, the two parties will officially launch a three-year plan to connect 15 million smart health devices in the second half of the year, further promoting the integration of AI medical equipment into JD HEALTH APP and HomeCare service system, achieving a full upgrade from device connection, data management to health services.
It is reported that since JD HEALTH and Jiangsu Yuyue Medical Equipment & Supply reached a comprehensive strategic cooperation in March of this year, the two parties have set a sales target of 10 billion over the next three years, jointly creating an industry growth benchmark. In the first half of the year, the collaborative results between the two parties continued to show in key categories such as blood sugar management, ECG monitoring, and respiratory oxygenation achieving significant growth. Among them, Yuyue CGM dynamic blood glucose meter and ECG monitor saw a year-on-year growth of over 200%, becoming high-growth categories in JD HEALTH's medical equipment business.
Related Articles

Jiangsu Hanbon Science and Technology (688755.SH): Shareholders such as Shanghai Pharmaron, Qingsheng Chi, etc. plan to reduce their total holdings by no more than 3%.

Jiangyin Electrical Alloy(300697.SZ) has received approval from the China Securities Regulatory Commission to issue convertible bonds.

Hunan Er-kang Pharmaceutical (300267.SZ): Sodium hydroxide raw material drug listing application approved.
Jiangsu Hanbon Science and Technology (688755.SH): Shareholders such as Shanghai Pharmaron, Qingsheng Chi, etc. plan to reduce their total holdings by no more than 3%.

Jiangyin Electrical Alloy(300697.SZ) has received approval from the China Securities Regulatory Commission to issue convertible bonds.

Hunan Er-kang Pharmaceutical (300267.SZ): Sodium hydroxide raw material drug listing application approved.

RECOMMEND





